Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$4.11
-0.5%		$4.59
$3.68
▼
$52.73
$5.15M1.6692,898 shs2,951 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.64
-6.6%		$0.77
$0.56
▼
$4.31
$19.68M0.5495,821 shs80,001 shs
GRDX
Entero Therapeutics
$2.90
-4.9%		$4.58
$1.08
▼
$6.93
$21.08M1.8159,220 shs62,788 shs
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
$0.28
+4.8%		$0.37
$0.25
▼
$3.05
$14.88M-0.051.25 million shs4.13 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-0.48%-6.38%-7.64%-16.46%-92.18%
Celularity, Inc. stock logo
CELU
Celularity
-6.57%-15.29%+5.13%-33.62%-80.45%
GRDX
Entero Therapeutics
-4.92%-4.61%-34.83%+15.08%+289,999,900.00%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
+4.80%-25.62%-31.20%-3.54%-88.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$4.11
-0.5%		$4.59
$3.68
▼
$52.73
$5.15M1.6692,898 shs2,951 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.64
-6.6%		$0.77
$0.56
▼
$4.31
$19.68M0.5495,821 shs80,001 shs
GRDX
Entero Therapeutics
$2.90
-4.9%		$4.58
$1.08
▼
$6.93
$21.08M1.8159,220 shs62,788 shs
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
$0.28
+4.8%		$0.37
$0.25
▼
$3.05
$14.88M-0.051.25 million shs4.13 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-0.48%-6.38%-7.64%-16.46%-92.18%
Celularity, Inc. stock logo
CELU
Celularity
-6.57%-15.29%+5.13%-33.62%-80.45%
GRDX
Entero Therapeutics
-4.92%-4.61%-34.83%+15.08%+289,999,900.00%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
+4.80%-25.62%-31.20%-3.54%-88.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
2.33
HoldN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
2.00
Hold$6.00844.44% Upside
GRDX
Entero Therapeutics
0.00
N/AN/AN/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
2.40
Hold$9.003,170.35% Upside

Current Analyst Ratings Breakdown

Latest APVO, CELU, GRDX, and MDCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/28/2026
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
Alliance Global Partners logo
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
7/8/2026
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/1/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
6/15/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
5/26/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
5/8/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/A$17.42 per shareN/A
Celularity, Inc. stock logo
CELU
Celularity
$26.55M0.69N/AN/A($1.32) per share-0.48
GRDX
Entero Therapeutics
$40K500.98N/AN/A$7.42 per share0.39
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$25.97M-$197.60N/AN/AN/AN/A-198.50%-117.06%8/10/2026 (Estimated)
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)
GRDX
Entero Therapeutics
-$6.39M-$1.88N/AN/AN/AN/A-49.81%-11.02%N/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)

Latest APVO, CELU, GRDX, and MDCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026N/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$6.02N/AN/AN/AN/AN/A
8/10/2026N/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$0.14N/AN/AN/AN/AN/A
5/27/2026Q1 2026
GRDX
Entero Therapeutics
N/A-$0.82N/A-$0.82N/A$0.04 million
5/14/2026Q1 2026
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$0.18-$0.31-$0.13-$0.31N/AN/A
5/13/2026Q1 2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$6.41-$6.41N/A-$6.41N/AN/A
5/1/2026Q4 2025
GRDX
Entero Therapeutics
N/A-$1.88N/A-$1.88N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
GRDX
Entero Therapeutics
N/AN/AN/AN/AN/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
3.36
3.36
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.15
0.15
GRDX
Entero Therapeutics
N/A
0.16
0.16
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A
1.22
1.22

Institutional Ownership

CompanyInstitutional Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
GRDX
Entero Therapeutics
12.30%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A

Insider Ownership

CompanyInsider Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.08%
Celularity, Inc. stock logo
CELU
Celularity
17.30%
GRDX
Entero Therapeutics
0.75%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
501.25 million1.25 millionNot Optionable
Celularity, Inc. stock logo
CELU
Celularity
22028.95 million23.94 millionOptionable
GRDX
Entero Therapeutics
96.91 million6.86 millionN/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A56.66 million52.07 millionN/A

Recent News About These Companies

Medicus Pharma Gets UAE Approval to Begin Phase 2 Endometriosis Drug trial
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/medicus-pharma-gets-uae-approval-120356136.html
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
July 31 at 9:32 AM  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1096361?snapi
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women ...
July 31 at 8:46 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/medicus-pharma-receives-uae-department-of-health-doh-authorization-to-proceed-with-novel-prospective-genomics-guided-precision-medicine-study-evaluating-teverelix-in-women-with-endometriosis-1036391973
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
July 31 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336735/0/en/medicus-pharma-receives-uae-department-of-health-doh-authorization-to-proceed-with-novel-prospective-genomics-guided-precision-medicine-study-evaluating-teverelix-in-women-with-end.html
Medicus Pharma Gets FDA Approval to Advance Phase 2b SkinJect Study
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/medicus-pharma-gets-fda-approval-124129399.html
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome
July 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/video/medicus-pharma-cleared-fda-registrational-160708111.html
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
July 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/medicus-pharma-receives-fda-study-may-proceed-letter-for-nda-enabling-registrational-skinject-study-in-patients-with-gorlin-syndrome-1036366818
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
July 27, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1096076?snapi
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333507/0/en/medicus-pharma-receives-fda-study-may-proceed-letter-for-nda-enabling-registrational-skinject-study-in-patients-with-gorlin-syndrome.html
Medicus Pharma CEO details Teverelix progress – ICYMI
July 18, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095661?snapi
Medicus Pharma advances Phase 2 study following FDA and IRB feedback
July 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/video/medicus-pharma-advances-phase-2-164803561.html
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
July 16, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095563?snapi
Medicus Pharma Receives FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Study in Acute Urinary Retention
July 16, 2026  |  quiverquant.comQ
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328360/0/en/medicus-pharma-receives-positive-fda-feedback-and-central-irb-approval-for-optimized-phase-2-teverelix-novel-study-in-acute-urinary-retention.html
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?
June 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/medicus-pharma-ltd-mdcx-stock-132036598.html
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026
June 22, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/06/60010800/medicus-pharma-to-to-highlight-skinject-phase-2-data-and-teverelix-clinical-advances-at-bio-2026
Medicus Pharma to Present Clinical and Regulatory Updates at 2026 Bio International Conference
June 22, 2026  |  quiverquant.comQ
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315195/0/en/medicus-pharma-to-showcase-skinject-registrational-strategy-and-teverelix-precision-medicine-program-at-bio-international-2026.html
Medicus Pharma advances Teverelix in prostate cancer - ICYMI
June 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1094197?snapi
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome
June 15, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1093907?snapi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$4.11 -0.02 (-0.48%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$3.65 -0.46 (-11.17%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Celularity stock logo

Celularity NASDAQ:CELU

$0.64 -0.04 (-6.57%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.65 +0.02 (+2.63%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Entero Therapeutics NASDAQ:GRDX

$2.90 -0.15 (-4.92%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$3.00 +0.10 (+3.45%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Medicus Pharma stock logo

Medicus Pharma NASDAQ:MDCX

$0.28 +0.01 (+4.80%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.28 +0.00 (+0.29%)
As of 07/31/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas